French ophthalmology laboratory Kôl launched Olisens®, the first messenger RNA eye drop for the treatment of corneal neovessels. This “antisense oligonucleotide”, inhibits IRS1, the protein that initiates the abnormal growth of neovessels in the cornea. Olisens is available thanks to a compassionate use authorization granted by ANSM. We have the pleasure of manufacturing it for them at Laboratoire Unither Coutances (Normandy) and accompany Kôl in Europe and internationally. About us Unither is the worldwide leader in sterile unit-dose production. Through our sites in North America, Europe and China, we can manage the development of a Blow-Fill-Seal (BFS) product from concept to manufacturing, providing the benefit of our development expertise and market intelligence. Every day, we provide innovative BFS technology solutions to improve customers’ products and extend existing product lines. We offer manufacturing capabilities and services to support the development and commercialization of orphan drugs. These services include regulatory support, analytical, full development, formulation, and process implementation services. We are committed to working closely with our clients to ensure that their orphan drugs are successfully developed, produced, and brought to market. Learn more about Laboratoires Kôl: https://www.laboratoires-kol.com/en
